Wells Fargo’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $217K | Buy |
46,691
+40,392
| +641% | +$105K | ﹤0.01% | 5156 |
|
|
2026
Q1 | $17.6K | Buy |
6,299
+2,208
| +54% | +$6.72K | ﹤0.01% | 5824 |
|
|
2025
Q4 | $17K | Hold |
4,091
| – | – | ﹤0.01% | 5830 |
|
|
2025
Q3 | $17.3K | Sell |
4,091
-271
| -6% | -$1.02K | ﹤0.01% | 5832 |
|
|
2025
Q2 | $9.2K | Sell |
4,362
-7,256
| -62% | -$10.9K | ﹤0.01% | 5973 |
|
|
2025
Q1 | $14.2K | Sell |
11,618
-5,748
| -33% | -$8.06K | ﹤0.01% | 5803 |
|
|
2024
Q4 | $22.4K | Buy |
17,366
+2,990
| +21% | +$7.17K | ﹤0.01% | 5735 |
|
|
2024
Q3 | $39.5K | Buy |
14,376
+8
| +0.1% | +$20 | ﹤0.01% | 5427 |
|
|
2024
Q2 | $32.5K | Buy |
14,368
+7,114
| +98% | +$21.6K | ﹤0.01% | 5438 |
|
|
2024
Q1 | $17.3K | Sell |
7,254
-328
| -4% | -$620 | ﹤0.01% | 5618 |
|
|
2023
Q4 | $12.6K | Sell |
7,582
-455
| -6% | -$882 | ﹤0.01% | 5773 |
|
|
2023
Q3 | $15.4K | Buy |
8,037
+2,588
| +47% | +$4.26K | ﹤0.01% | 5686 |
|
|
2023
Q2 | $7.85K | Sell |
5,449
-20,729
| -79% | -$35.2K | ﹤0.01% | 5966 |
|
|
2023
Q1 | $55K | Buy |
26,178
+19,769
| +308% | +$31.9K | ﹤0.01% | 5118 |
|
|
2022
Q4 | $7.24K | Sell |
6,409
-2,113
| -25% | -$2.81K | ﹤0.01% | 5671 |
|
|
2022
Q3 | $13K | Sell |
8,522
-6
| -0.1% | -$11 | ﹤0.01% | 5576 |
|
|
2022
Q2 | $11K | Buy |
8,528
+24
| +0.3% | +$35 | ﹤0.01% | 5706 |
|
|
2022
Q1 | $13K | Buy |
8,504
+1
| +0% | +$2 | ﹤0.01% | 6171 |
|
|
2021
Q4 | $18K | Buy |
8,503
+6
| +0.1% | +$17 | ﹤0.01% | 6360 |
|
|
2021
Q3 | $33K | Sell |
8,497
-3,543
| -29% | -$12K | ﹤0.01% | 5779 |
|
|
2021
Q2 | $39K | Sell |
12,040
-8,288
| -41% | -$29.5K | ﹤0.01% | 5652 |
|
|
2021
Q1 | $45K | Sell |
20,328
-76,487
| -79% | -$171K | ﹤0.01% | 5856 |
|
|
2020
Q4 | $217K | Buy |
96,815
+39,571
| +69% | +$104K | ﹤0.01% | 5038 |
|
|
2020
Q3 | $153K | Sell |
57,244
-10,702
| -16% | -$30K | ﹤0.01% | 5093 |
|
|
2020
Q2 | $209K | Buy |
67,946
+22,288
| +49% | +$56.1K | ﹤0.01% | 4884 |
|
|
2020
Q1 | $89K | Buy |
45,658
+14,188
| +45% | +$34.5K | ﹤0.01% | 5117 |
|
|
2019
Q4 | $90K | Buy |
31,470
+2,708
| +9% | +$9.41K | ﹤0.01% | 5342 |
|
|
2019
Q3 | $106K | Buy |
28,762
+22,028
| +327% | +$79.6K | ﹤0.01% | 5295 |
|
|
2019
Q2 | $28K | Buy |
6,734
+242
| +4% | +$1.05K | ﹤0.01% | 5709 |
|
|
2019
Q1 | $34K | Sell |
6,492
-2,137
| -25% | -$10.3K | ﹤0.01% | 5406 |
|
|
2018
Q4 | $30K | Sell |
8,629
-49,842
| -85% | -$238K | ﹤0.01% | 5676 |
|
|
2018
Q3 | $352K | Buy |
58,471
+18,336
| +46% | +$101K | ﹤0.01% | 4680 |
|
|
2018
Q2 | $255K | Buy |
40,135
+29,553
| +279% | +$144K | ﹤0.01% | 4893 |
|
|
2018
Q1 | $50K | Sell |
10,582
-300
| -3% | -$1.4K | ﹤0.01% | 5563 |
|
|
2017
Q4 | $36K | Sell |
10,882
-1,000
| -8% | -$2.53K | ﹤0.01% | 5635 |
|
|
2017
Q3 | $25K | Hold |
11,882
| – | – | ﹤0.01% | 5652 |
|
|
2017
Q2 | $30K | Hold |
11,882
| – | – | ﹤0.01% | 5533 |
|
|
2017
Q1 | $27K | Buy |
11,882
+7,162
| +152% | +$10.8K | ﹤0.01% | 5638 |
|
|
2016
Q4 | $4K | Hold |
4,720
| – | – | ﹤0.01% | 5987 |
|
|
2016
Q3 | $5K | Buy |
4,720
+1,000
| +27% | +$1.78K | ﹤0.01% | 5907 |
|
|
2016
Q2 | $6K | Hold |
3,720
| – | – | ﹤0.01% | 5780 |
|
|
2016
Q1 | $6K | Hold |
3,720
| – | – | ﹤0.01% | 5834 |
|
|
2015
Q4 | $6K | Sell |
3,720
-830
| -18% | -$1.9K | ﹤0.01% | 5844 |
|
|
2015
Q3 | $11K | Sell |
4,550
-2,735
| -38% | -$6.45K | ﹤0.01% | 5703 |
|
|
2015
Q2 | $20K | Buy |
7,285
+2,489
| +52% | +$7.5K | ﹤0.01% | 5594 |
|
|
2015
Q1 | $16K | Buy |
4,796
+340
| +8% | +$1.22K | ﹤0.01% | 5466 |
|
|
2014
Q4 | $16K | Buy |
4,456
+83
| +2% | +$367 | ﹤0.01% | 5450 |
|
|
2014
Q3 | $22K | Sell |
4,373
-1,508
| -26% | -$11.7K | ﹤0.01% | 5251 |
|
|
2014
Q2 | $81K | Sell |
5,881
-2,755
| -32% | -$34.3K | ﹤0.01% | 4763 |
|
|
2014
Q1 | $132K | Buy |
8,636
+6,516
| +307% | +$92.8K | ﹤0.01% | 4532 |
|
|
2013
Q4 | $17K | Hold |
2,120
| – | – | ﹤0.01% | 5059 |
|
|
2013
Q3 | $21K | Buy |
+2,120
| New | +$14.3K | ﹤0.01% | 4943 |
|
Other funds holding GALT
WANY
Wells Fargo's GALT Position: Q2 2026 in Review
Wells Fargo increased its Galectin Therapeutics (GALT) stake by 641% in Q2 2026, buying an estimated $105K and bringing the position to 46,691 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #5156.
Wells Fargo first reported a position in GALT in Q3 2013 and has held it in 52 quarters since. The position peaked at $352K in Q3 2018. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Wells Fargo held 46,691 shares of Galectin Therapeutics worth $217K as of Q2 2026.
- Wells Fargo bought 40,392 Galectin Therapeutics shares in Q2 2026, an estimated $105K.
- Galectin Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5156 holding.
- Wells Fargo first reported a position in Galectin Therapeutics in Q3 2013 and has held it in 52 quarters since.
- Wells Fargo's Galectin Therapeutics position peaked at $352K in Q3 2018.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.